1.55
0.11 (7.64%)
0.11 (7.64%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 751,467 |
|
|||||
News | - | ||||||
Day High | 1.6481 | Low High |
|||||
Day Low | 1.4101 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aditxt Inc | ADTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.46 | 1.4101 | 1.6481 | 1.515 | 1.44 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,247 | 751,467 | $ 1.55 | $ 1,166,840 | - | 0.1242 - 28.49 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:56:44 | formt | 100 | $ 1.55 | USD |
Aditxt Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 6.66M | 4.30M | 4.24M | $ 105.03k | $ - | -112.50 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 29.90% |
Aditxt News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.45 | 1.6481 | 1.30 | 1.39 | 104,762 | 0.10 | 6.9% |
1 Month | 1.4799 | 1.6481 | 1.2001 | 1.42 | 181,060 | 0.0701 | 4.74% |
3 Months | 1.87 | 1.96 | 1.00 | 1.52 | 168,609 | -0.32 | -17.11% |
6 Months | 0.1526 | 28.49 | 0.1245 | 1.53 | 4,069,144 | 1.40 | 915.73% |
1 Year | 0.4225 | 28.49 | 0.1242 | 0.9453538 | 3,752,785 | 1.13 | 266.86% |
3 Years | 5.28 | 28.49 | 0.1242 | 1.95 | 2,952,398 | -3.73 | -70.64% |
5 Years | 5.28 | 28.49 | 0.1242 | 1.95 | 2,952,398 | -3.73 | -70.64% |
Aditxt Description
Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |